News|Articles|November 8, 2025

HCPLive Coverage Recap: NASPGHAN 2025 Annual Meeting

HCPLive highlights key pediatric gastroenterology updates from NASPGHAN 2025, with continuing coverage to follow.

At the 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, held November 5–8 at the Sheraton Grand Chicago in Chicago, Illinois, clinicians, researchers, and allied health professionals gathered to share the latest data, clinical updates, and expert perspectives in pediatric gastroenterology, hepatology, and nutrition.

Related to this article

October 6th, 2026

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

October 7th, 2026

Why Alcohol-Associated Liver Disease May Not Have Peaked, With Brian Lee, MD

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

October 6th, 2026

Targeting the Disease Mechanism in PFIC, With Hisamitsu Hayashi, PhD

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

October 6th, 2026

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

October 6th, 2026

RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

October 6th, 2026

10 Hepatology Headlines You Missed in Q3 2026

Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.

October 5th, 2026

5 Gastroenterology Headlines You Missed in September 2026

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

October 5th, 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.